Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: A case report

[1]  E. Lee,et al.  Advances in Management of Brain and Leptomeningeal Metastases , 2020, Current Neurology and Neuroscience Reports.

[2]  Brian L. Shaw,et al.  Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis , 2020, Nature Medicine.

[3]  J. Lee,et al.  Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). , 2020 .

[4]  P. Brastianos,et al.  Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions , 2020, Pigment cell & melanoma research.

[5]  Christopher M. Fife,et al.  Immune Checkpoint Blockade – How Does It Work in Brain Metastases? , 2019, Front. Mol. Neurosci..

[6]  R. Jain,et al.  The blood–brain barrier and blood–tumour barrier in brain tumours and metastases , 2019, Nature Reviews Cancer.

[7]  B. Kamińska,et al.  Immune Microenvironment of Brain Metastases—Are Microglia and Other Brain Macrophages Little Helpers? , 2019, Front. Immunol..

[8]  J. Beijnen,et al.  Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review , 2019, BMC Cancer.

[9]  J. Schellens,et al.  Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid , 2019, Journal of pharmaceutical and biomedical analysis.

[10]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[11]  R. Niu,et al.  JAK2 and PD‐L1 Amplification Enhance the Dynamic Expression of PD‐L1 in Triple‐negative Breast Cancer , 2018, Clinical breast cancer.

[12]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[13]  S. Chuai,et al.  Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  R. Amaria,et al.  Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2 , 2018, ESMO Open.

[15]  S. Culine,et al.  Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Loi,et al.  Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis , 2016, Breast Cancer Research.

[17]  H. Heinzl,et al.  Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases , 2016, Oncoimmunology.

[18]  G. Hortobagyi,et al.  Leptomeningeal disease and breast cancer: the importance of tumor subtype , 2014, Breast Cancer Research and Treatment.

[19]  S. Taillibert,et al.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors , 2013, Surgical neurology international.

[20]  M. Dimopoulos,et al.  Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis , 2013, Breast Cancer Research and Treatment.

[21]  P. Wen,et al.  Epidemiology of Brain Metastases , 2012, Current Oncology Reports.

[22]  T. Illidge,et al.  Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab , 2011 .

[23]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[24]  J. B. Blacklock,et al.  Cytokine Responses to Intraventricular Injection of Interleukin 2 into Patients with Leptomeningeal Carcinomatosis: Rapid Induction of Tumor Necrosis Factor α, Interleukin 1β, Interleukin 6, γ-Interferon, and Soluble Interleukin 2 Receptor (Mr 55,000 Protein) , 1992 .

[25]  J. Baars,et al.  Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. , 1991, Surgical neurology.

[26]  Y. Kluger,et al.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jill S Barnholtz-Sloan,et al.  Brain metastases: epidemiology. , 2018, Handbook of clinical neurology.